Benzenesulfonamide

Benzenesulfonamide

SCHEMBL6989482

Cc1noc2ccccc12.NS(=O)(=O)c1ccccc1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 12/20 0.52
CA9 Q16790 12/20 0.52
CA12 O43570 10/20 0.52
CA1 P00915 10/20 0.52
CA3 P07451 3/20 0.52
CA4 P22748 3/20 0.52
CA6 P23280 3/20 0.52
CA5A P35218 3/20 0.52
CA7 P43166 3/20 0.52
CA13 Q8N1Q1 3/20 0.52
CA14 Q9ULX7 3/20 0.52
CA5B Q9Y2D0 3/20 0.52
PLA2G7 Q13093 1/20 0.52
BRD4 O60885 1/20 0.50
LMNA P02545 2/20 0.47
MAOB P27338 1/20 0.47
PTGS2 P35354 4/20 0.47
MT-CO2 P00403 1/20 0.47
ADRB2 P07550 1/20 0.47
ADRB1 P08588 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzenesulfonamide SCHEMBL9273975 0.94 BRD4 (0.46) CA2CA9CA12CA1CA3
SCHEMBL12331 0.82 LMNA (0.44) CA2CA9CA12CA1CA3
SCHEMBL5918772 0.80 LMNA (0.43) CA2CA9CA12CA1CA3
SCHEMBL20084004 0.77 BRD4 (0.47) CA2CA9CA12CA1CA3
SCHEMBL4314858 0.75 BRD4 (0.54) BRD4EDNRBEDNRAPOLB
Benzenesulfonamide SCHEMBL28194516 0.72 CA2 (0.89) CA2CA9CA12CA1CA3
SCHEMBL29490377 0.72 CA2 (0.56) CA2CA9CA12CA1CA3
SCHEMBL1499919 0.72 CA2 (0.56) CA2CA9CA12CA1CA3
Benzenesulfonamide SCHEMBL6868390 0.72 CA2 (1.00) CA2CA9CA12CA1CA3
SCHEMBL19479299 0.72 CA2 (1.00) CA2CA9CA12CA1CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0646115-B1 HETEROCYCLIC-CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2003-01-22 EP disclosed
US-6498255-B2 CHOLINESTERASE INHIBITORS; COGNITION ACTIVATORS; ALZHEIMER'S DISEASE; E.G., 3-(2-(1-(PHENYLMETHYL)-4-PIPERIDINYL)ETHYL)-1,2-BENZISOXAZOLE PFIZER INC. 2002-12-24 US disclosed
US-20020028834-A1 Heterocyclic-cyclic amine derivatives VILLALOBOS ANABELLA (US) 2002-03-07 US disclosed
US-6326382-B1 CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE EISAI CO., LTD (JP) 2001-12-04 US disclosed
US-5750542-A Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors PFIZER (US) 1998-05-12 US disclosed
US-5538984-A Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors PFIZER INC. (US) 1996-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028834-A1 Heterocyclic-cyclic amine derivatives BCHE, ACHE, CHRM1 CA2 2383/4885CA9 2178/4885CA12 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.